GGrantIndex
Sort

4,870 grants matching glp 1

Vascular CT contrast agent development

$843,622
Michael A Davis · Nextrast, Inc. · R44 · FY2021 · HL

Translational Development of a Targeted and Stroma-penetrating Nanoparticle Drug for Pancreatic Cancer Therapy

$841,919
Lei Zhu · Migra-Therapeutics, Llc · R44 · FY2023 · CA

The Next-Generation Developmental and Reproductive Toxicology (DART) Assay using High-Content Analysis of Genetically Diverse C. elegans Populations

$841,749
Evan Hegarty · Vivoverse, Llc · R44 · FY2024 · ES

Novel non-narcotic analgesic for acute and chronic pain

$840,427
Nicolas Guillermo Bazan · South Rampart Pharma, Llc · R42 · FY2021 · NS

Novel non-narcotic analgesic for acute and chronic pain

$840,427
Nicolas Guillermo Bazan · South Rampart Pharma, Llc · R42 · FY2022 · NS

Large animal therapy studies

$839,884
William A. Beltran · University Of Pennsylvania · R24 · FY2012 · EY

Project 1 - Profectus Biosciences, Inc.

$839,059
John H Eldridge · Henry M. Jackson Fdn For The Adv Mil/Med · U19 · FY2020 · AI

Targeting superbugs: discovery and development of new broad-spectrum lipopeptides

$838,537
Jian Li · Monash University · R01 · FY2015 · AI

Appalachian Node

$838,320
Jane M Liebschutz · University Of Pittsburgh At Pittsburgh · UG1 · FY2025 · DA

Animal Medicine COVID Support

$837,751
Ruth Woodward · National Institute Of Allergy And Infectious Diseases · ZIG · FY2021 · AI

Development of a potent and selective oral ENPP1 inhibitor for oncology

$836,231
Mohan Rao Kaadige · Stingray Therapeutics, Inc. · R44 · FY2023 · CA

Therapeutic Thrombin Analogs

$834,603
Erik Ian Tucker · Aronora, Inc. · R44 · FY2014 · HL

Optimization of Lead BKIs for Cryptosporidiosis Therapy

$834,465
Wesley C Van Voorhis · University Of Washington · R01 · FY2021 · AI

Glial Progenitor Cells for Treatment of ALS

$833,878
Linda L Kelley · Johns Hopkins University · U01 · FY2010 · NS

The optimization of compounds that selectively inhibit protein synthesis for the

$833,819
Cathy A Swindlehurst · Novomedix, Inc. · R44 · FY2013 · CA

Combination Therapy with Semaglutide and Anti-Amyloid Antibodies for Alzheimers Disease

$833,674
Cynthia A Lemere · Brigham And Women'S Hospital · R01 · FY2025 · AG

Pulmonary Valved Graft with Regeneration Potential for Pediatric Patients

$833,493
Ajay Houde · Annoviant, Inc · R44 · FY2024 · HL

Long-acting ghrelin for the treatment of cancer cachexia

$832,924
Tarik Soliman · Extend Biosciences, Inc. · R44 · FY2017 · CA

Enhancement of Beta Cell Function with Pharmacologic and Sleep Apnea Treatment

$832,900
David A Ehrmann · University Of Chicago · U01 · FY2015 · DK

Manufacturing and Toxicology Studies of DNA and Protein Vaccines

$832,766
Gary R Ostroff · Univ Of Massachusetts Med Sch Worcester · U19 · FY2011 · AI

Development of novel anti-biofilm compounds for treating chronic wounds

$832,651
Daina Zeng · Agile Sciences, Inc. · R44 · FY2016 · AI

First-in-class TREM-1 inhibitors for neovascular retinal diseases

$830,491
Alexander B Sigalov · Signablok, Inc. · R44 · FY2025 · EY

A Novel Peptide Therapeutic for Obesity

$829,401
Neil A Fanger · Virtici, Llc · R44 · FY2018 · DK

Targeting superbugs: discovery and development of new broad-spectrum lipopeptides

$829,212
Jian Li · Monash University · R01 · FY2014 · AI

Development of an engineered CCL20 protein as a lead therapeutic molecule for psoriasis

$829,097
Brian F Volkman · Xlock Biosciences, Llc · R44 · FY2021 · AR